I have scoured Pubmed and UTSE but I have not found any anecdotal nor per reviewed analysis on how the different subtypes of MAOIs (RIMA's for example)interact with DMT or is there simply not a big enough difference to worry about?

Would Selegine, a selective inhibitor of MAO-B interact differently than the older irreversible and non-selective monoamine oxidase inhibitors?

Would Moclebimide as a RIMA interact differently?

I have no idea or experience to share but it got me thinking that perhaps this should be explored as a harm reduction point of potential interest.

Are we being too general in our categorization when discussing interactions with MAOI'S?

I will continue to explore this but if anyone with a better understanding of the pharmacodynamic and pharmacokinetic variations within different subgroups of MAOI's can point me to the motherlode I'd appreciate it.

Thanks for reading
cheers